The following is a summary of the TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript:

Financial Performance:

• TG Therapeutics reported total revenue for Q1 2024 of $63.5 million, with U.S. Briumvi net product revenue accounting for $50.5 million.

• The company's operating expenses were approximately $58 million, leading to a slight net loss around $10.7 million, or $0.07 per share.

• As of Q1 2024, TG Therapeutics had a cash, cash equivalents, and investment securities total of $209.8 million.

• Full-year guidance has been adjusted to $270 million - $290 million due to current trends and robust growth.

Business Progress:

• TG Therapeutics secured the VA contract for Briumvi, opening it up to more healthcare providers.

• The company has newly issued patents extending protection for Briumvi through 2042, expanding future potential for the drug.

• The partnership with Precision BioSciences offers potential treatment for certain autoimmune diseases, expanding TG Therapeutics' reach.

• TG Therapeutics is focusing on increasing the convenience of Briumvi with the development of a subcutaneous version.

• The company expects to start clinical trials for azer-cel, an allogeneic CD19 CAR T cell therapy for autoimmune diseases and other non-oncology indications, within the year.

• Approximately 160 new prescribers and 65 new accounts were added in the first quarter, with broad adoption occurring in over 450 centers and over 800 unique prescribers.

• Plans to continue investment in Briumvi's launch are underway, projecting further profitability in coming quarters.

More details: TG Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.